Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

Trial Profile

Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2016

At a glance

  • Drugs Lansoprazole (Primary)
  • Indications Duodenal ulcer; Gastric ulcer; Gastritis
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 10 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top